By mapping neurological circuits in the brain, an international team of researchers created a model of brain dysfunction that could help to better guide a surgical treatment for Parkinson’s disease and other brain disorders. Findings were published in Nature Nuroscience, in the study “Mapping dysfunctional circuits…
Patient enrollment has started in a Phase 1/2 clinical trial evaluating 18F-OP-801, Ashvattha Therapeutics’ investigational imaging agent to visualize brain inflammation in people with Parkinson’s disease and other neurodegenerative conditions, the company said in a press release. The ongoing trial (NCT05395624), which…
Targeting reactive astrocytes — star-shaped cells in the brain that play a supportive role for neurons but can promote brain inflammation when deregulated — could pave the way for novel therapies for neurodegenerative conditions like Parkinson’s disease, according to the findings of a new study. The study found that…
A potential anti-inflammatory therapy for Parkinson’s disease may be evaluated in clinical trials within the next year. The investigative treatment combines a low-dose formulation of interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF), two natural signaling molecules made in the body to help coordinate the activity of immune cells.
Olatec Therapeutics will launch a Phase 2 clinical trial in the U.K. to investigate the potential of oral dapansutrile to slow or stop Parkinson’s disease progression by reducing inflammation in the brain. The study, made possible by a grant from the U.K.-based Cure Parkinson’s, will begin in…
The selective loss of dopamine-producing nerve cells in one side of the brain of mice, to mimic Parkinson’s disease, impacted the length of movement sequences on the opposite side of the body, but not the same side, a study shows. The study’s researchers discovered two distinct populations of these…
An observational clinical trial in Canada that’s investigating the role of the small intestinal microbiome — the population of natural microorganisms living in the gastrointestinal tract — in Parkinson’s disease is now recruiting participants. Its researchers specifically aim to determine if Parkinson’s patients carry a unique microbial and metabolic…
A first participant has been dosed in Arvinas’ first-in-human Phase 1 trial testing ARV-102, its oral therapy candidate for neurodegenerative conditions, including Parkinson’s disease and progressive supranuclear palsy, or PSP, an atypical parkinsonian disorder. The Phase 1 trial — now enrolling healthy volunteers at the Centre for Human Drug…
Computer scientists at the University of North Carolina at Chapel Hill have developed software and an augmented reality (AR) headset that allows clinicians to analyze movement in people with Parkinson’s disease to help guide their physical therapy. Clinicians can also use their own AR headsets to immerse themselves in…
Suppressing astrocytes’ release of the pro-inflammatory molecule interleukin (IL)-6 reduced the loss of dopaminergic neurons, the nerve cells that are progressively lost in Parkinson’s disease, a new study reports. In Parkinson’s, astrocytes, the star-shaped cells that provide physical support for neurons in the brain, secrete high levels of IL-6…
Get regular updates to your inbox.
